Xeris Biopharma Holdings, Inc. 8-K

What Happened
Xeris Biopharma Holdings, Inc. (XERS) filed an 8-K on June 5, 2026 reporting the voting results from its 2026 Annual Meeting held June 4, 2026. As of the record date (April 14, 2026) there were 172,625,762 shares outstanding; 128,268,073 shares were present virtually or by proxy, constituting a quorum. The board’s two Class II director nominees were elected, Ernst & Young LLP was ratified as auditor, and the company’s executive compensation was approved in a non-binding “say-on-pay” vote.

Key Details

• Shares outstanding (record date April 14, 2026): 172,625,762; shares present at meeting: 128,268,073.
• Director elections (Class II, terms to 2029):
  • Dawn Halkuff — For: 62,581,577; Withhold: 24,906,166; Broker non-votes: 40,780,330.
  • John Johnson — For: 52,665,077; Withhold: 34,822,666; Broker non-votes: 40,780,330.
• Auditor ratification: Ernst & Young LLP ratified — For: 125,789,818; Against: 1,032,530; Abstain: 1,445,725.
• Say-on-Pay (advisory): Approved — For: 82,230,204; Against: 4,658,035; Abstain: 599,504; Broker non-votes: 40,780,330.
• Proxy Statement filing referenced: April 23, 2026.

Why It Matters
These results confirm the company’s governance slate and auditor for fiscal 2026 and show stockholder approval of executive compensation on an advisory basis. The presence of substantial broker non-votes (40,780,330) is notable because those shares were present but not voted on certain matters, which can affect vote totals on contested or close items. Ratification of Ernst & Young indicates continued external audit oversight for the year ending December 31, 2026.